Share Price and Basic Stock Data
Last Updated: November 22, 2025, 10:55 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Brawn Biotech Ltd, operating in the pharmaceuticals industry, recorded a market capitalization of ₹6.30 Cr and a share price of ₹21.0. The company has seen fluctuating sales over the past quarters, with reported revenues of ₹2.89 Cr in March 2022, peaking at ₹7.77 Cr in September 2022, before declining to ₹4.75 Cr in March 2023. The sales trend indicates volatility, with the most recent quarter (September 2023) recording ₹2.92 Cr. The trailing twelve months (TTM) sales stood at ₹15.20 Cr, showing a decrease from ₹22.23 Cr in March 2023 and ₹16.49 Cr in March 2024. This decline highlights challenges in maintaining consistent revenue generation, likely influenced by external market conditions and internal operational issues.
Profitability and Efficiency Metrics
Brawn Biotech’s profitability metrics reflect significant challenges. The operating profit margin (OPM) was recorded at -24.34%, indicating that expenses far exceed revenues. The company has consistently reported negative operating profits since March 2022, with a low of -0.58 in December 2023. The net profit margins also remained negative, with a loss of ₹1.02 Cr in the most recent fiscal year. Furthermore, the interest coverage ratio (ICR) was an alarming -454.00x, suggesting extreme difficulties in meeting interest obligations. The return on equity (ROE) was reported at an impressive 41.3%, but this figure is misleading given the significant losses, indicating that while equity returns appear strong, they are not translating into actual profit generation. Overall, profitability remains a critical area needing substantial improvement.
Balance Sheet Strength and Financial Ratios
The balance sheet of Brawn Biotech reveals a concerning financial structure. The company reported no borrowings or reserves, emphasizing a lack of financial cushion to absorb losses. The current ratio stood at 1.88, indicating reasonable liquidity, but this is offset by an alarming cash conversion cycle (CCC) of 160.70 days, suggesting inefficiencies in managing working capital. The price-to-book value (P/BV) ratio was 1.45x, which, while not excessively high, indicates that the market values the company at a premium relative to its book value. The return on capital employed (ROCE) was reported at 42.5%, but this figure is overshadowed by the negative profitability metrics, revealing that capital is not being effectively utilized to generate revenue. These factors contribute to a precarious financial situation, necessitating immediate strategic interventions.
Shareholding Pattern and Investor Confidence
Brawn Biotech’s shareholding pattern reflects a stable structure, with promoters holding 53.66% of the company, indicating strong insider confidence. The public holds 45.99%, while domestic institutional investors (DIIs) have a minimal stake of 0.35%. The number of shareholders has decreased from 6,275 in December 2022 to 3,958 by March 2025, indicating potential investor fatigue or concerns regarding the company’s performance. The consistent promoter holding suggests a commitment to the company’s future, but the lack of institutional backing raises questions about broader market confidence. This disparity may affect the company’s ability to raise capital for growth initiatives, further complicating its operational challenges.
Outlook, Risks, and Final Insight
Brawn Biotech faces a challenging outlook characterized by significant risks and operational hurdles. The company must address its profitability issues to regain investor confidence and stabilize revenue streams. The absence of borrowings presents a double-edged sword; while it avoids interest burdens, it limits growth potential. The high cash conversion cycle and negative operating margins indicate inefficiencies that need addressing. However, the strong promoter support and high ROE can serve as a foundation for potential turnaround strategies. Should the company successfully implement operational improvements and enhance revenue generation, it may reverse its current trajectory. Conversely, continued losses and declining revenues could lead to further shareholder attrition and potential liquidity issues, underscoring the need for immediate action to restore financial health.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Brawn Biotech Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 159 Cr. | 127 | 247/84.3 | 35.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,497 Cr. | 413 | 479/192 | 93.1 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.6 Cr. | 44.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 39.5 Cr. | 27.0 | 29.1/17.0 | 94.1 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,140.56 Cr | 1,177.13 | 52.88 | 202.41 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.89 | 0.12 | 7.77 | 6.31 | 4.75 | 7.29 | 2.92 | 2.84 | 3.45 | 4.06 | 3.30 | 3.84 | 2.26 |
| Expenses | 2.61 | 0.09 | 8.11 | 6.32 | 4.88 | 7.45 | 3.31 | 3.42 | 3.84 | 4.56 | 3.62 | 4.24 | 2.81 |
| Operating Profit | 0.28 | 0.03 | -0.34 | -0.01 | -0.13 | -0.16 | -0.39 | -0.58 | -0.39 | -0.50 | -0.32 | -0.40 | -0.55 |
| OPM % | 9.69% | 25.00% | -4.38% | -0.16% | -2.74% | -2.19% | -13.36% | -20.42% | -11.30% | -12.32% | -9.70% | -10.42% | -24.34% |
| Other Income | -0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.09 |
| Interest | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.02 | 0.00 | 0.02 | 0.03 | 0.04 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Profit before tax | 0.16 | 0.03 | -0.36 | -0.04 | -0.17 | -0.18 | -0.42 | -0.61 | -0.34 | -0.53 | -0.35 | -0.43 | -0.49 |
| Tax % | -293.75% | 0.00% | -2.78% | 0.00% | 258.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | 0.63 | 0.02 | -0.35 | -0.04 | -0.61 | -0.17 | -0.42 | -0.61 | -0.34 | -0.53 | -0.34 | -0.43 | -0.49 |
| EPS in Rs | 2.10 | 0.07 | -1.17 | -0.13 | -2.03 | -0.57 | -1.40 | -2.03 | -1.13 | -1.77 | -1.13 | -1.43 | -1.63 |
Last Updated: May 31, 2025, 6:38 am
Below is a detailed analysis of the quarterly data for Brawn Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 2.26 Cr.. The value appears to be declining and may need further review. It has decreased from 3.84 Cr. (Dec 2024) to 2.26 Cr., marking a decrease of 1.58 Cr..
- For Expenses, as of Mar 2025, the value is 2.81 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.24 Cr. (Dec 2024) to 2.81 Cr., marking a decrease of 1.43 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.55 Cr.. The value appears to be declining and may need further review. It has decreased from -0.40 Cr. (Dec 2024) to -0.55 Cr., marking a decrease of 0.15 Cr..
- For OPM %, as of Mar 2025, the value is -24.34%. The value appears to be declining and may need further review. It has decreased from -10.42% (Dec 2024) to -24.34%, marking a decrease of 13.92%.
- For Other Income, as of Mar 2025, the value is 0.09 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Dec 2024) to 0.09 Cr., marking an increase of 0.09 Cr..
- For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Depreciation, as of Mar 2025, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.03 Cr..
- For Profit before tax, as of Mar 2025, the value is -0.49 Cr.. The value appears to be declining and may need further review. It has decreased from -0.43 Cr. (Dec 2024) to -0.49 Cr., marking a decrease of 0.06 Cr..
- For Tax %, as of Mar 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00%.
- For Net Profit, as of Mar 2025, the value is -0.49 Cr.. The value appears to be declining and may need further review. It has decreased from -0.43 Cr. (Dec 2024) to -0.49 Cr., marking a decrease of 0.06 Cr..
- For EPS in Rs, as of Mar 2025, the value is -1.63. The value appears to be declining and may need further review. It has decreased from -1.43 (Dec 2024) to -1.63, marking a decrease of 0.20.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:43 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34.42 | 38.65 | 46.88 | 59.78 | 55.71 | 65.18 | 49.62 | 34.98 | 8.53 | 22.23 | 16.49 | 13.46 | 15.20 |
| Expenses | 33.97 | 38.09 | 45.44 | 58.53 | 53.75 | 64.01 | 48.89 | 35.58 | 10.53 | 22.53 | 17.95 | 15.23 | 16.29 |
| Operating Profit | 0.45 | 0.56 | 1.44 | 1.25 | 1.96 | 1.17 | 0.73 | -0.60 | -2.00 | -0.30 | -1.46 | -1.77 | -1.09 |
| OPM % | 1.31% | 1.45% | 3.07% | 2.09% | 3.52% | 1.80% | 1.47% | -1.72% | -23.45% | -1.35% | -8.85% | -13.15% | -7.17% |
| Other Income | -0.07 | 0.04 | 0.01 | 0.61 | 0.09 | 0.74 | 0.17 | 0.31 | 0.00 | 0.01 | 0.08 | 0.09 | 0.18 |
| Interest | 0.14 | 0.10 | 0.11 | 0.07 | 0.06 | 0.07 | 0.05 | 0.04 | 0.06 | 0.01 | 0.06 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.11 | 0.10 | 0.11 | 0.12 |
| Profit before tax | 0.23 | 0.47 | 1.31 | 1.76 | 1.96 | 1.81 | 0.82 | -0.36 | -2.11 | -0.41 | -1.54 | -1.79 | -1.03 |
| Tax % | 39.13% | 40.43% | 27.48% | 20.45% | 34.69% | 26.52% | 28.05% | 55.56% | -22.27% | 109.76% | -19.48% | -3.35% | |
| Net Profit | 0.14 | 0.28 | 0.95 | 1.39 | 1.28 | 1.33 | 0.59 | -0.55 | -1.64 | -0.87 | -1.25 | -1.74 | -1.02 |
| EPS in Rs | 0.47 | 0.93 | 3.17 | 4.63 | 4.27 | 4.43 | 1.97 | -1.83 | -5.47 | -2.90 | -4.17 | -5.80 | -3.39 |
| Dividend Payout % | 0.00% | 0.00% | 31.58% | 32.37% | 23.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | 239.29% | 46.32% | -7.91% | 3.91% | -55.64% | -193.22% | -198.18% | 46.95% | -43.68% | -39.20% |
| Change in YoY Net Profit Growth (%) | 0.00% | 139.29% | -192.97% | -54.23% | 11.82% | -59.55% | -137.58% | -4.96% | 245.13% | -90.63% | 4.48% |
Brawn Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -10% |
| 5 Years: | -23% |
| 3 Years: | 16% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -3% |
| TTM: | 46% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | -3% |
| 3 Years: | 5% |
| 1 Year: | 15% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -18% |
| 3 Years: | -23% |
| Last Year: | -43% |
Last Updated: September 5, 2025, 2:46 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88.65 | 87.07 | 71.63 | 79.50 | 98.60 | 92.17 | 110.34 | 96.83 | 120.24 | 87.35 | 85.88 | 92.47 |
| Inventory Days | 22.14 | 11.17 | 4.50 | 2.59 | 2.62 | 2.12 | 3.38 | 3.16 | 261.82 | 91.20 | 153.02 | 320.33 |
| Days Payable | 87.79 | 73.72 | 44.59 | 47.70 | 83.93 | 64.58 | 74.47 | 32.34 | 224.66 | 123.19 | 144.12 | 252.10 |
| Cash Conversion Cycle | 23.01 | 24.52 | 31.54 | 34.39 | 17.29 | 29.72 | 39.25 | 67.65 | 157.41 | 55.36 | 94.78 | 160.70 |
| Working Capital Days | 15.48 | 15.87 | 18.92 | 28.21 | 43.37 | 42.06 | 58.04 | 77.53 | 241.76 | 80.62 | 137.90 | 216.40 |
| ROCE % | 24.89% | 11.91% | 26.54% | 29.28% | 27.77% | 23.08% | 9.71% | -3.55% | -25.61% | -5.91% | -25.86% | -42.52% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -5.87 | -4.15 | -3.04 | -5.25 | -1.55 |
| Diluted EPS (Rs.) | -5.87 | -4.15 | -3.04 | -5.25 | -1.55 |
| Cash EPS (Rs.) | -5.61 | -3.83 | -2.53 | -5.30 | -1.72 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 11.21 | 16.88 | 21.03 | 24.07 | 29.31 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 11.21 | 16.88 | 21.03 | 24.07 | 29.31 |
| Revenue From Operations / Share (Rs.) | 44.88 | 54.98 | 74.09 | 28.73 | 116.57 |
| PBDIT / Share (Rs.) | -5.60 | -4.80 | -0.98 | -6.67 | -0.96 |
| PBIT / Share (Rs.) | -5.98 | -5.13 | -1.34 | -6.85 | -1.08 |
| PBT / Share (Rs.) | -5.99 | -5.15 | -1.37 | -7.06 | -1.20 |
| Net Profit / Share (Rs.) | -5.99 | -4.16 | -2.89 | -5.48 | -1.84 |
| PBDIT Margin (%) | -12.47 | -8.73 | -1.32 | -23.22 | -0.82 |
| PBIT Margin (%) | -13.32 | -9.33 | -1.81 | -23.84 | -0.92 |
| PBT Margin (%) | -13.35 | -9.36 | -1.85 | -24.56 | -1.02 |
| Net Profit Margin (%) | -13.35 | -7.56 | -3.90 | -19.07 | -1.57 |
| Return on Networth / Equity (%) | -53.47 | -24.61 | -13.75 | -22.77 | -6.26 |
| Return on Capital Employeed (%) | -16.07 | -19.06 | -6.21 | -27.53 | -3.60 |
| Return On Assets (%) | -8.77 | -8.54 | -5.97 | -11.92 | -3.96 |
| Asset Turnover Ratio (%) | 0.76 | 1.13 | 1.57 | 0.62 | 2.05 |
| Current Ratio (X) | 1.88 | 2.02 | 1.67 | 1.93 | 2.60 |
| Quick Ratio (X) | 0.75 | 1.09 | 1.07 | 1.18 | 2.54 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | 5.09 |
| Interest Coverage Ratio (X) | -454.00 | -380.33 | -35.76 | -32.06 | -7.83 |
| Interest Coverage Ratio (Post Tax) (X) | -484.97 | -328.11 | -104.52 | -25.33 | -13.91 |
| Enterprise Value (Cr.) | 4.68 | 5.60 | 4.53 | 4.98 | 6.23 |
| EV / Net Operating Revenue (X) | 0.34 | 0.33 | 0.20 | 0.57 | 0.17 |
| EV / EBITDA (X) | -2.78 | -3.89 | -15.39 | -2.49 | -21.54 |
| MarketCap / Net Operating Revenue (X) | 0.36 | 0.36 | 0.22 | 0.60 | 0.18 |
| Price / BV (X) | 1.45 | 1.18 | 0.78 | 0.72 | 0.75 |
| Price / Net Operating Revenue (X) | 0.36 | 0.36 | 0.22 | 0.60 | 0.18 |
| EarningsYield | -0.36 | -0.20 | -0.17 | -0.31 | -0.08 |
After reviewing the key financial ratios for Brawn Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -5.87. This value is below the healthy minimum of 5. It has decreased from -4.15 (Mar 24) to -5.87, marking a decrease of 1.72.
- For Diluted EPS (Rs.), as of Mar 25, the value is -5.87. This value is below the healthy minimum of 5. It has decreased from -4.15 (Mar 24) to -5.87, marking a decrease of 1.72.
- For Cash EPS (Rs.), as of Mar 25, the value is -5.61. This value is below the healthy minimum of 3. It has decreased from -3.83 (Mar 24) to -5.61, marking a decrease of 1.78.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.21. It has decreased from 16.88 (Mar 24) to 11.21, marking a decrease of 5.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.21. It has decreased from 16.88 (Mar 24) to 11.21, marking a decrease of 5.67.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 44.88. It has decreased from 54.98 (Mar 24) to 44.88, marking a decrease of 10.10.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -5.60. This value is below the healthy minimum of 2. It has decreased from -4.80 (Mar 24) to -5.60, marking a decrease of 0.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is -5.98. This value is below the healthy minimum of 0. It has decreased from -5.13 (Mar 24) to -5.98, marking a decrease of 0.85.
- For PBT / Share (Rs.), as of Mar 25, the value is -5.99. This value is below the healthy minimum of 0. It has decreased from -5.15 (Mar 24) to -5.99, marking a decrease of 0.84.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -5.99. This value is below the healthy minimum of 2. It has decreased from -4.16 (Mar 24) to -5.99, marking a decrease of 1.83.
- For PBDIT Margin (%), as of Mar 25, the value is -12.47. This value is below the healthy minimum of 10. It has decreased from -8.73 (Mar 24) to -12.47, marking a decrease of 3.74.
- For PBIT Margin (%), as of Mar 25, the value is -13.32. This value is below the healthy minimum of 10. It has decreased from -9.33 (Mar 24) to -13.32, marking a decrease of 3.99.
- For PBT Margin (%), as of Mar 25, the value is -13.35. This value is below the healthy minimum of 10. It has decreased from -9.36 (Mar 24) to -13.35, marking a decrease of 3.99.
- For Net Profit Margin (%), as of Mar 25, the value is -13.35. This value is below the healthy minimum of 5. It has decreased from -7.56 (Mar 24) to -13.35, marking a decrease of 5.79.
- For Return on Networth / Equity (%), as of Mar 25, the value is -53.47. This value is below the healthy minimum of 15. It has decreased from -24.61 (Mar 24) to -53.47, marking a decrease of 28.86.
- For Return on Capital Employeed (%), as of Mar 25, the value is -16.07. This value is below the healthy minimum of 10. It has increased from -19.06 (Mar 24) to -16.07, marking an increase of 2.99.
- For Return On Assets (%), as of Mar 25, the value is -8.77. This value is below the healthy minimum of 5. It has decreased from -8.54 (Mar 24) to -8.77, marking a decrease of 0.23.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has decreased from 1.13 (Mar 24) to 0.76, marking a decrease of 0.37.
- For Current Ratio (X), as of Mar 25, the value is 1.88. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.88, marking a decrease of 0.14.
- For Quick Ratio (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.75, marking a decrease of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -454.00. This value is below the healthy minimum of 3. It has decreased from -380.33 (Mar 24) to -454.00, marking a decrease of 73.67.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -484.97. This value is below the healthy minimum of 3. It has decreased from -328.11 (Mar 24) to -484.97, marking a decrease of 156.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4.68. It has decreased from 5.60 (Mar 24) to 4.68, marking a decrease of 0.92.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 1. It has increased from 0.33 (Mar 24) to 0.34, marking an increase of 0.01.
- For EV / EBITDA (X), as of Mar 25, the value is -2.78. This value is below the healthy minimum of 5. It has increased from -3.89 (Mar 24) to -2.78, marking an increase of 1.11.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.36.
- For Price / BV (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 1.18 (Mar 24) to 1.45, marking an increase of 0.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.36.
- For EarningsYield, as of Mar 25, the value is -0.36. This value is below the healthy minimum of 5. It has decreased from -0.20 (Mar 24) to -0.36, marking a decrease of 0.16.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Brawn Biotech Ltd:
- Net Profit Margin: -13.35%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -16.07% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -53.47% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -484.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.75
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.88)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -13.35%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | C-64, First Floor, New Delhi Delhi 110024 | solution@brawnbiotech.com http://www.brawnbiotech.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Brij Raj Gupta | Director |
| Mrs. Brij Bala Gupta | Director |
| Mr. Mayank Jain | Independent Director |
| Mrs. Pooja Jha | Independent Director |